Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2C | P18825 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | DRD2 | P14416 | 4/20 | 0.51 |
| ▸ | DRD3 | P35462 | 4/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | EGFR | P00533 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
| ▸ | DRD4 | P21917 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | NCF1 | P14598 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | MC4R | P32245 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31376167 | 1.00 | ADRA2C (0.55) | ADRA2CKMT2AMEN1DRD2DRD3 | |
| Hydrochloric Acid SCHEMBL5154521 | 0.98 | ADRA2C (0.53) | ADRA2CKMT2AMEN1DRD2DRD3 | |
| SCHEMBL1737649 | 0.93 | NCF1 (0.55) | ADRA2CKMT2AMEN1DRD2DRD3 | |
| SCHEMBL29946548 | 0.84 | DRD2 (0.47) | ADRA2CKMT2AMEN1DRD2DRD3 | |
| SCHEMBL3582553 | 0.84 | DRD2 (0.47) | ADRA2CKMT2AMEN1DRD2DRD3 | |
| SCHEMBL24159517 | 0.83 | ADRA2C (0.49) | ADRA2CKMT2AMEN1DRD2DRD3 | |
| SCHEMBL3220834 | 0.82 | ALDH1A1 (0.50) | KMT2AMEN1MAPK1LMNAEGFR | |
| SCHEMBL23064633 | 0.82 | MEN1 (0.48) | KMT2AMEN1MAPK1LMNAEGFR | |
| SCHEMBL27978816 | 0.81 | ALDH1A1 (0.47) | KMT2AMEN1MAPK1LMNAMAPT | |
| SCHEMBL31167266 | 0.81 | KEAP1 (0.52) | KMT2AMEN1MAPK1LMNAEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 163 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12582645-B2 | Chemokine CXCR4 receptor modulators and uses related thereto | EMORY UNIVERSITY (US) | 2026-03-24 | — | — | US | disclosed |
| US-20240316034-A1 | Chemokine CXCR4 Receptor Modulators and Uses Related Thereto | UNIV EMORY (US) | 2024-09-26 | — | — | US | disclosed |
| US-20230112832-A1 | Chemokine CXCR4 Receptor Modulators and Uses Related Thereto | UNIV EMORY (US) | 2023-04-13 | — | — | US | disclosed |
| US-20230112832-A1 | Chemokine CXCR4 Receptor Modulators and Uses Related Thereto | UNIV EMORY (US) | 2023-04-13 | — | — | US | disclosed |
| US-11497744-B2 | Chemokine CXCR4 receptor modulators and uses related thereto | EMORY UNIVERSITY (US) | 2022-11-15 | — | — | US | disclosed |
| WO-2022226667-A1 | SUBSTITUTED AMINO PYRIDINE COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2022-11-03 | — | — | WO | disclosed |
| EP-3770148-A1 | RECEPTOR INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF | Beijing Tide Pharmaceutical Co., Ltd. (CN) | 2021-01-27 | — | — | EP | disclosed |
| US-10813939-B2 | Bromodomain inhibitor as adjuvant in cancer immunotherapy | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2020-10-27 | — | — | US | disclosed |
| US-10676484-B2 | Compositions and methods for treating leukemia | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-06-09 | — | — | US | disclosed |
| US-20200148702-A1 | COMPOSITIONS AND METHODS FOR TREATING NEOPLASIA, INFLAMMATORY DISEASE AND OTHER DISORDERS | DANA FARBER CANCER INST INC (US) | 2020-05-14 | — | — | US | disclosed |
| US-6197773-B1 | HEADACHES; ANTIDEPRESSANTS | PFIZER INC | 2001-03-06 | — | — | US | disclosed |
| EP-0952154-A2 | N-acyl and N-aroyl aralkyl amides | Pfizer Products Inc. (US) | 1999-10-27 | — | — | EP | disclosed |
| CN-1231661-A | Lactams and imides of aralkyl and arylalkylene heterocycles | PFIZER (US) | 1999-10-13 | — | — | CN | disclosed |
| EP-0929528-A1 | ARALKYL AND ARALKYLIDENE HETEROCYCLIC LACTAMS AND IMIDES | PFIZER INC. (US) | 1999-07-21 | — | — | EP | disclosed |
| EP-0894085-A1 | BENZYL(IDENE)-LACTAM DERIVATIVES, THEIR PREPARATION AND THEIR USE AS SELECTIVE (ANT)AGONISTS OF 5-HT1A- AND/OR 5-HT1D RECEPTORS | PFIZER INC. (US) | 1999-02-03 | — | — | EP | disclosed |
| WO-1998014433-A1 | ARALKYL AND ARALKYLIDENE HETEROCYCLIC LACTAMS AND IMIDES | PFIZER INC. (US) | 1998-04-09 | — | — | WO | disclosed |
| EP-0810220-A1 | Arylacrylamide derivatives as 5HT1 agonists or antagonists | PFIZER INC. (US) | 1997-12-03 | — | — | EP | disclosed |
| WO-1997036867-A1 | BENZYL(IDENE)-LACTAM DERIVATIVES, THEIR PREPARATION AND THEIR USE AS SELECTIVE (ANT)AGONISTS OF 5-HT1A- AND/OR 5-HT1D RECEPTORS | PFIZER INC. (US) | 1997-10-09 | — | — | WO | disclosed |
| EP-0232399-A1 | NEW AMINES, PROCESS FOR THEIR MANUFACTURE, THEIR USE AND MEDICINES CONTAINING THEM | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 1987-08-19 | — | — | EP | disclosed |
| WO-1987001114-A2 | NEW AMINES, PROCESS FOR THEIR MANUFACTURE, THEIR USE AND MEDICINES CONTAINING THEM | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1987-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240316034-A1 | Chemokine CXCR4 Receptor Modulators and Uses Related Thereto | CXCR4, CXCL12, CXCR1 | ADRA2C 2238/4885KMT2A 4253/4885MEN1 4543/4885 |
| US-10813939-B2 | Bromodomain inhibitor as adjuvant in cancer immunotherapy | BRDT, BRD4, BRD1 | ADRA2C 3610/4885KMT2A 415/4885MEN1 4108/4885 |
| US-10676484-B2 | Compositions and methods for treating leukemia | MCL1, ABL1, FLT3 | ADRA2C 4388/4885KMT2A 231/4885MEN1 2413/4885 |
| US-11497744-B2 | Chemokine CXCR4 receptor modulators and uses related thereto | CXCR4, CXCL12, CXCR1 | ADRA2C 2238/4885KMT2A 4253/4885MEN1 4543/4885 |
| US-20230112832-A1 | Chemokine CXCR4 Receptor Modulators and Uses Related Thereto | CXCR4, CXCL12, CXCR1 | ADRA2C 2238/4885KMT2A 4253/4885MEN1 4543/4885 |
| US-20200148702-A1 | COMPOSITIONS AND METHODS FOR TREATING NEOPLASIA, INFLAMMATORY DISEASE AND OTHER DISORDERS | BRPF3, EP300, BRD3 | ADRA2C 4610/4885KMT2A 134/4885MEN1 1913/4885 |
| US-12582645-B2 | Chemokine CXCR4 receptor modulators and uses related thereto | CXCR4, CXCR2, CXCR1 | ADRA2C 727/4885KMT2A 2692/4885MEN1 4454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.